Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05739123 · ClinicalTrials.gov registry record
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
A clinical trial of Pregnancy Related and Pregnancy Complications, sponsored by Sumitomo Pharma Switzerland.
- Recruiting
- Registry status
- 728
- Enrollment target
- 1
- Study location
NCT05739123: Recruiting study of Pregnancy Related and Pregnancy Complications, sponsored by Sumitomo Pharma Switzerland.
NCT05739123 is a study of Pregnancy Related and Pregnancy Complications that is actively recruiting participants, run by Sumitomo Pharma Switzerland. The registered enrollment target is 728 participants, below the 1,956-participant average among 99 other Pregnancy Related trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05739123, a study of Pregnancy Related and Pregnancy Complications, is actively recruiting participants, sponsored by Sumitomo Pharma Switzerland.
- RECRUITING
- Registry status
- 728 participants
- Enrollment target
- 1
- Study location
Study Summary
The Relugolix Pregnancy Registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant outcomes. Data will be collected from enrolled pregnant women and the healthcare providers (HCPs) involved in their care or the care of their infants, if applicable.
Primary Outcome
Comparison of rate of MCM between cohorts
Conditions Studied
Interventions
- DRUG Relugolix-Containing Product
Study Locations (1)
North Carolina
- PPD - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 728 participants |
| Start Date | 2023-05-08 |
| Est. Completion | 2033-05 |
What NCT05739123 shows while recruiting
NCT05739123 is an observational study that tracks outcomes without assigning an intervention. The registered 728 participants enrollment target is mid-sized for trials with a published cap, below the 1,956-participant average among 99 other Pregnancy Related trials with a reported enrollment target (63% lower).
The record links to 3 conditions, with Pregnancy Related appearing as the primary indexed condition, and to 1 intervention - of which Relugolix-Containing Product is the first listed.
NCT05739123 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05739123 about?
NCT05739123 is a clinical study titled "Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring". The Relugolix Pregnancy Registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant outcomes. Data will be collected from enrolled pregnant women and the healthcar...
What is the current status of trial NCT05739123?
This trial is currently recruiting. The enrollment target is 728 participants. The study started on 2023-05-08. Estimated completion is 2033-05.
What conditions does trial NCT05739123 study?
This clinical trial studies the following conditions: Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk.
What interventions are being tested in trial NCT05739123?
The interventions under investigation include: Relugolix-Containing Product (DRUG).
Who is sponsoring clinical trial NCT05739123?
This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05739123 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy Related
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05739123's enrollment target sits among peer trials
728 23rd of 99 higher than 77 of 99 other Pregnancy Related trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pregnancy Related trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Antenatal Support for Iron Deficiency Anemia
RECRUITING · Phase 4
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
Mobile Application-based Exercise Intervention for Pregnant Women
RECRUITING · NA
-
Rigorous Evaluation of Yes and Know, a Fully Virtual Sexual Health and Well-Being Intervention for Youth
RECRUITING · NA
-
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
RECRUITING
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- NCT06433765 · 728 participants
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
- NCT06660342 · 728 participants
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI